Srdan Verstovsek, MD, provides information on the diagnosis and treatment of patients with polycythemia vera: Case 2

Experts review the case of a 68-year-old woman diagnosed with primary myelofibrosis.

The phase 3 Shorespan-007 trial will compare bomedemstat with hydroxyurea in patients with treatment-naive essential thrombocythemia.

Tebapivat, a novel pyruvate kinase activator, is being investigated for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.

Imetelstat sustained red blood cell transfusion independence in patients with lower-risk myelodysplastic syndrome, with most responders experiencing durable responses.

During a Case-Based Roundtable® event, Gabriela S. Hobbs, MD, surveyed physicians on the disease features that are most challenging in primary myelofibrosis in the first article of a 2-part series.

During a Case-Based Roundtable® event, Jeanne M. Palmer, MD, moderated a discussion on challenging symptoms of myelofibrosis and when to initiate treatment with JAK inhibitors.